EP Patent

EP2068825A1 — Controlled release delivery system for nasal application of neurotransmitters

Assigned to M&P Patent AG · Expires 2009-06-17 · 17y expired

What this patent protects

This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of t…

USPTO Abstract

This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.

Drugs covered by this patent

Patent Metadata

Patent number
EP2068825A1
Jurisdiction
EP
Classification
—
Expires
2009-06-17
Drug substance claim
No
Drug product claim
No
Assignee
M&P Patent AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.